ObjectiveTo evaluate the use of pulmonary inhalation-perfusion scintigraphy as an
alternative method of investigation and follow-up in patients with
bronchopleural fistula (BPF).Materials and MethodsNine patients with BPFs were treated through the off-label use of a
transcatheter atrial septal defect occluder, placed endoscopically, and were
followed with pulmonary inhalation-perfusion scintigraphy, involving
inhalation, via a nebulizer, of 900-1300 MBq (25-35 mCi) of
technetium-99m-labeled diethylenetriaminepentaacetic acid and single-photon
emission computed tomography with a dual-head gamma camera.ResultsIn two cases, there was a residual air leak that was not identified by
bronchoscopy or the methylene blue test but was detected only by pulmonary
inhalation-perfusion scintigraphy. Those results correlated with the
evolution of the patients, both of whom showed late signs of air leak, which
confirmed the scintigraphy findings. In the patients with complete
resolution of symptoms and fistula closure seen on bronchoscopy, the
scintigraphy was completely negative. In cases of failure to close the BPF,
the scintigraphy confirmed the persistence of the air leak. In two patients,
scintigraphy was the only method to show residual BPF, the fistula no longer
being seen on bronchoscopy.ConclusionWe found pulmonary inhalation-perfusion scintigraphy to be a useful tool for
identifying a residual BPF, as well as being an alternative method of
investigating BPFs and of monitoring the affected patients.